Arnon Kater, MD, PhD

Articles

Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL

January 8th 2025

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Recent Guideline Updates in the Frontline Management of CLL

January 6th 2025

Dr Niemann provides an overview of the evolving treatment landscape of CLL.